NCT02909777: Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

NCT02909777
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 1 Year to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase (Part A)
Exclusions: Patient with unstable untreated CNS metastasis; Patients over the age of 21; Patient who has received prior CUDC-907 therapy
https://ClinicalTrials.gov/show/NCT02909777

Comments are closed.

Up ↑